Detail Information of Xenobiotics

General Information of Xenobiotics (ID: XEO00035)
Xenobiotics Name
Fenofibrate
Xenobiotics Type
Pharmaceutical Agent(s)
Classification
Approved/Marketed Drug
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=3339"></iframe>
3D MOL 2D MOL
PubChem CID
3339
DME(s) Modulated by This Xenobiotics
DME(s) Inhibited by This Xenobiotics
Acetyl-CoA synthetase (ACSS2) DME Info Homo sapiens [1]
Alcohol dehydrogenase class-I gamma (ADH1C) DME Info Homo sapiens [1]
Alcohol dehydrogenase class-II (ADH4) DME Info Homo sapiens [1]
Small intestine reductase (AKR1B10) DME Info Homo sapiens [2]
Alkaline phosphatase (ALPL) DME Info Homo sapiens [1]
Cytosolic branched aminotransferase (BCAT1) DME Info Homo sapiens [3]
Cytochrome P450 2C8 (CYP2C8) DME Info Homo sapiens [4]
S-adenosylmethionine synthase 2 (MAT2A) DME Info Homo sapiens [5]
Proline dehydrogenase 1 (PRODH) DME Info Homo sapiens [1]
DME(s) Induced by This Xenobiotics
Aldo-keto reductase 1C2 (AKR1C2) DME Info Homo sapiens [3]
Asparagine synthetase (ASNS) DME Info Homo sapiens [3]
Mephenytoin 4-hydroxylase (CYP2C19) DME Info Homo sapiens [1]
Cytochrome P450 3A7 (CYP3A7) DME Info Homo sapiens [6]
Lauric acid omega-hydroxylase (CYP4A11) DME Info Homo sapiens [1]
Fatty acid desaturase 1 (FADS1) DME Info Homo sapiens [7]
Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DME Info Homo sapiens [1]
Peroxisomal multifunctional enzyme 2 (HSD17B4) DME Info Homo sapiens [1]
Nitric oxide synthase endothelial (NOS3) DME Info Homo sapiens [8]
Phosphoglucomutase 1 (PGM1) DME Info Homo sapiens [9]
Serum paraoxonase/arylesterase 1 (PON1) DME Info Homo sapiens [10]
NADPH-cytochrome P450 reductase (CPR) DME Info Homo sapiens [1]
Tryptophan oxygenase (TRPO) DME Info Homo sapiens [1]
Thioredoxin reductase TR1 (TXNRD1) DME Info Homo sapiens [3]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DME Info Homo sapiens [1]
UDP-glucuronosyltransferase 1A3 (UGT1A3) DME Info Homo sapiens [11]
UDP-glucuronosyltransferase 2B4 (UGT2B4) DME Info Homo sapiens [11]
References
1 Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
2 Inhibiting wild-type and C299S mutant AKR1B10; a homologue of aldose reductase upregulated in cancers. Eur J Pharmacol. 2008 Apr 28;584(2-3):213-21.
3 Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
4 Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78.
5 In vitro and in vivo effects of the PPAR-alpha agonists fenofibrate and retinoic acid in endometrial cancer. Mol Cancer. 2006 Mar 28;5:13.
6 Use of mRNA expression to detect the induction of drug metabolising enzymes in rat and human hepatocytes. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):86-96.
7 Delta5 desaturase mRNA levels are increased by simvastatin via SREBP-1 at early stages, not via PPARalpha, in THP-1 cells. Eur J Pharmacol. 2007 Oct 1;571(2-3):97-105.
8 Fenofibrate suppresses microvascular inflammation and apoptosis through adenosine monophosphate-activated protein kinase activation. Metabolism. 2011 Apr;60(4):513-22.
9 Linalool is a PPARalpha ligand that reduces plasma TG levels and rewires the hepatic transcriptome and plasma metabolome. J Lipid Res. 2014 Jun;55(6):1098-110.
10 The effect of fenofibrate on serum paraoxonase activity and inflammatory markers in patients with combined hyperlipidemia. Kardiol Pol. 2005 Jun;62(6):526-30.
11 Human UDP-glucuronosyltransferase (UGT)1A3 enzyme conjugates chenodeoxycholic acid in the liver. Hepatology. 2006 Nov;44(5):1158-70.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.